Full Text
HTA225 Optimizing HTA Outcomes in Cost-Effectiveness Markets: A Case Study of Axicabtagene Ciloleucel

Abstract

Authors

SR Webb J Avissar VK Brennan

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×